EUCTR2012-001850-24-AT进行中（未招募）1 期
A prospective randomized phase II trial of FOLFIRINOX alone versus FOLFIRINOX followed by radiochemotherapy in patients with locally advanced, primarily inoperable pancreatic cancer
ABCSG (Austrian Breast & Colorectal Cancer Study Group)0 个研究点目标入组 112 人开始时间: 2012年7月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 112
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Informed consent signed prior to randomization and prior to any study specific procedure
- •Patients with histologically proven PDAC, classified as locally advanced, primarily inoperable disease;
- •patients with suspicious peripancreatic lymph nodes at initial staging, accessible by surgery are included in the study
- •Tumor must have at least one diameter of 15 mm assessed with conventional imaging techniques (e.g. CT, MRI) and at least on diameter of 10 mm measured by contrast enhanced CT
- •Patients scheduled for neoadjuvant treatment by the interdisciplinary tumor board
- •Radiologically determinable disease defined by RECIST version 1.1 within 4 weeks prior to randomization
- •ECOG performance status =1 or Karnofsky =70%
- •Adequate hematologic function, as follows (= 7d prior to randomization):
- •o absolute neutrophil count (ANC) =1.5 x 109/L (in case ANC is not routinely measured, as alternatively relative neutrophil count > 50% is acceptable)
- •o white blood cell count (WBC) = 3.0 x 109/L
- •o platelet count = 100 x 109/L
- •o haemoglobin = 9 x g/dL
- •Adequate renal function, as follows (= 7d prior to randomization):
- •o creatinine = 1.5 x upper limit of normal (ULN) or GFR >50mL/min
- •Adequate hepatic function, as follows (= 7d prior to randomization):
- •o aspartate aminotransferase (ASAT) = 5 x ULN
- •o alanine aminotransferase (ALAT) = 5 x ULN
- •o total bilirubin = 1.5 x ULN
- •Any age = 18 = 75 years
- •Ability to comply with the protocol and attend follow up
- •Women of childbearing potential must have a negative serum pregnancy test done within 1 week prior to study drug administration. Women are not considered of childbearing potential in case that the following criteria applies:
- •o after having undergone hysterectomy and/or bilateral ovarectomy and/or bilateral tubal ligation
- •o = 60 years
- •o with FSH and E2 in the postmenopausal range
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 112
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 112
排除标准
- •External biliary drain (Common bile duct stenting allowed)
- •Major surgery within 4 weeks prior to start of study treatment
- •Any past or current history of other malignancies (except in situ carcinoma, non-metastatic non-melanomatous skin cancers) less than 2 years prior to randomization
- •Any radiological suspicion, or histological proof of distant metastases or extra-pancreatic disease other than regional lymph node enlargement at initial staging
- •Any chemo- or radiotherapy for PDAC prior to study inclusion
- •Concurrent or prior systemic antitumor therapy within the last 2 years
- •Active infection requiring systemic treatment or any uncontrolled infections < 14 days prior to randomization
- •Concurrent administration of other IMP during treatment phase
- •Concurrent participation in another clinical trial with the same primary endpoint
- •Pregnancy, lactation, women of childbearing potential not willing to use effective means of contraception until 6 months after completion of study treatment
- •Male patients not willing to use effective means of contraception until three months after completion of study treatment
- •Previous irradiation within the actual fields of planned radiotherapy
- •Any known hypersensitivity/allergic reaction to any of the components of study treatments
- •Any severe and/or uncontrolled medical conditions including but not limited to:
- •o Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction = 12 months prior to enrolment, serious uncontrolled cardiac arrhythmia
- •o Acute and/or chronic, active infectious disorders and non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by this study therapy
- •o Active disorders of skin and/or mucosa and/or ocular and/or GI disorders > Grade 1
- •o Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, risk associated with study participation or IMP administration, or which, in the judgment of the investigator, would make the patient inappropriate for this study participation
研究者
相似试验
已完成
2 期
Randomized phase II trial of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with KRAS wild metastatic colorectal cancer refractory to oxaliplatin and bevacizumab with exploratory analysis to predict treatment efficacy and prognosisColorectal cancerJPRN-UMIN000005216West Japan Oncology Group200
进行中（未招募）
1 期
Evaluation of the efficacy of a combinaison treatment based upon immunotherapy + chemotherapy to treat patient with a stomach cancerAdvanced gastric or gastro-oesophageal junction adenocarcinomaMedDRA version: 20.0 Level: LLT Classification code 10042080 Term: Stomach cancer System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10026476 Term: Malignant neoplasm of stomach System Organ Class: 100000004864EUCTR2018-002014-13-FRFédération Francophone de Cancérologie Digestive94
进行中（未招募）
不适用
A randomized phase II study of FOLFORI plus or not CETUXIMAB in elderly advanced colorectal cancer patients.Elderly mestatic colorectal cancer patients, Wild-type KRAS ,70-80 years of age, ECOG 0-1.MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000477-23-ITAZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
已完成
2 期
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer(WJOG9216G)first-line treatment in patients with metastatic colorectal cancerJPRN-UMIN000026527West Japan Oncology Group120
进行中（未招募）
2 期
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment in patients with metastatic colorectal cancer (WJOG9216G)JPRN-jRCTs041180166Kito Yosuke120